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AN ASSOCIATION between levels of
circulating immune complexes (CIC) and
disease activity has been reported in
several types ofcancer (Robins & Baldwin,
1978). The antigen components of CIC
have been characterized in some virus-
induced animal tumours and shown to be
tumour products (Tucker et al., 1978;
Theofilopoulos et al., 1978). In human
cancer, components of CIC have only been
identified in a few instances, where a par-
ticular antigen such as CEA (Harvey et al.,
1978) or ACTH (Havemann et al., 1979)
had been specifically sought.
Several assays for CIC depend on the
ability of polyethylene glycol (PEG) to
precipitate immune complexes from serum
under conditions in which either free anti-
body or free antigen are soluble (Creighton
et al., 1973; Zubler et al., 1977; Digeon et
al., 1977; Poulton et al., 1978). It was pro-
posed that individual components of CIC
might be identified by analysis of PEG
precipitates. This paper describes Na
Dod SO4 polyacrylamide slab gel electro-
phoresis (PAGE) analysis of PEG pre-
cipitates of serum from patients with
Hodgkin's disease and non-Hodgkin's
lymphoma, and identification of a protein
the presence of which correlates with
disease activity.
The patients studied were attending the
Department of Medical Oncology at Char-
ing Cross Hospital for treatment of
Hodgkin's disease and non-Hodgkin's
lymphoma. Control sera were obtained
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from healthy laboratory and nursing staff,
patients with other malignancies, and
hospital inpatients and outpatients with
non-malignant conditions. Serum was
stored (before processing) for up to 14
days at 4°C' after addition of 0'5%
sodium azide.
3.500 PEG precipitation was performed
by a modification ofthe method of Digeon
et al. (1977). 160 plof serum was added to
540 1l 0d1M borate buffer (pH 8.4) and
mixedwith 700 1l of70, PEG 6000 (BDH)
in borate buffer. After standing overnight
at 4°C and washing in 3-5% PEG, the
precipitate was taken up in 0-IN NaOH
for measurement ofabsorbance at 280 nm.
The protein was then reprecipitated in
10% trichloracetic acid and examined by
PAGE (Studier, 1973) in non-reducing
conditions using the discontinuous buffer
system (Laemmli, 1970). Apparent mol.
wts were determined by electrophoresis
under reducing conditions. The gels were
stained for protein with Coomassie blue.
The components of PEG precipitates
were demonstrated by PAGE in which
proteins are separated according to their
mol. wt. Normal appearances are shown
in Fig. 1, Track 4. These were similar to
those in 31 other healthy volunteers (not
shown).
Hodykin's disease
When sera from patients with Hodgkin's
disease were examined an additional pro-
tein (T23) with an apparent mol. wt of
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* Serum sample positive for T23.
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LP =lymphocyte predominance, NS =nodular
sclerosis, MC =mixed cellularity, LD =lymphocyte
depletion NC =not classified.
FIG. 1-10% PAGE of 3-5% PEG precipi-
tates of serum. A. indicates the position
of T23. Track 1 contains material from a
patient with Stage IIIB Hodgkin's disease
before treatment. Track 2, after 4 days' and
Track 3, after 12 days' chemotherapy.
Track 4, a normal volunteer. The small
lhorizontal arrows on the left indicate the
position of mol. wt markers.
23,000 was identified. The presence of
T23 correlated with disease activity. This
is illustrated in Fig. 1, in which T23 was
present before treatment and disappeared
with successful cytotoxic chemotherapy.
Of 19 patients with Hodgkin's disease who
were studied (Table I) T23 was detected in
7/9 with active disease, but in only 3/11
in complete remission. Of these 3, one
relapsed within 1 month of the positive
result, a second became positive 3 weeks
after stopping chemotherapy and re-
lapsed clinically 7 months later. The third
patient remains clinically free from disease
1 year after the positive result.
Non-Hodgkin's lymphoma
A protein of the same apparent mol. wt
as found in Hodgkin's disease was also
present in serum of some patients with
non-Hodgkin's lymphoma. This will be
FIG. 2.88-5% PAGE of 3-5% PEG precipi-
tates of serum from a 59-year-old patient
with histiocytic diffuse (immunoblastic)
lymphoma involving marrow and lymph
nodes. Track 1, before treatment. Track 2,
10 days after starting treatment. Track 3,
on achieving a complete response by con-
ventional physical and haematological
criteria after 3 weeks' therapy.
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TABLE II.-T23 innon-Hodgkin's
lymiphoma
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* Serum sample positivse for T23.
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U =un(lifferentiated, LPDD =lymphocytic poorly
(lifferentiated diffuse, LWDD =lymphocytic well
(lifferentiated diffuse, LHD =lymphocytic-histio-
cytic diffuse, HD =histiocytic diffuse, LPDN =
lymplhocytic poorly differentiated nodular, LWDN =
lymphocytic well differentiated nodular.
referred to similarly as T23. Fig. 2 illus-
trates how T23 disappeared from the
serum of a patient with an immuno-
blastic lymphoma as tumour involving the
marrow responded to cytotoxic chemo-
therapy, allowing the restoration of
haemopoiesis. Table II shows that T23
was identified in 10/16 patients with
active disease, but in none of 8 in complete
remission.
Non-lymphoreticular neoplasms
T23 was found in 8/41 patients. These
single serum samples taken at random in
the course ofthe diseaseincluded 3positive
patients with carcinoma of the colon and
one eaclh with carcinoma of the bronchus,
carcinoma of the ovary, adenocarcinoma
of uinknown origin, hypernephroma and
Ewing's sarcoma.
Nlon-malignant conditions
T23 wasfound in onepatient withherpes
zoster among 15 with various non-
malignant conditions.
?,1
A protein (T23) of 23,000 mol. wt has
been identified in the serum of patients
with Hodgkin's disease, non-Hodgkin's
lymphoma, a few other malignancies and
in one patient with herpes zoster. In these
preliminary studies, identification of T23
correlated well with disease status in
malignant lymphoma and was occasion-
ally predictive ofrelapse.
The fact that T23 was found most
readily in material precipitated from
serum by 355% PEG is compatible with
the presence of T23 in the form of an
immune complex which is then split up by
the conditions required for PAGE. How-
ever, several proteins are precipitated
from normal serum in these conditions
(Fig. 1, Track 4) indicating that T23
could also be isolated because it is com-
plexed with a material other than an
antibody or by virtue of its individual
physicochemical characteristics.
Experiments to investigate these alter-
natives and for further clinical and im-
munological characterization of T23 are
in progress. It seems likely that more
specific and sensitive assays for T23 can be
developed, permitting investigations of
its site of production and of whether its
early promise as a tumour marker can be
confirmed and extended.
We are grateful to Professor K. D. Bagshawe and
Dr E. S. Newlands for permission to study their
patients.
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